Toyocamycin 产品活性：Toyocamycin (Vengicide) 是链霉菌类产生的腺苷类似物，是 X 盒结合蛋白 1 (XBP1) 抑制剂。Toyocamycin 可阻断 RNA 合成和核糖体功能，并诱导凋亡 (apoptosis)。Toyocamycin 影响 IRE1α-XBP1 通路，抑制 XBP1 mRNA 断裂 (IC50=80 nM)，不影响 IRE1α 自身磷酸化。Toyocamycin 特异性抑制 CDK9，IC50 为 79 nM。 产品来源： https://www.medchemexpress.cn/toyocamycin.html 研究领域：Cell Cycle/DNA Damage | Anti-infection | Apoptosis 作用靶点：IRE1 | Fungal | Antibiotic | Apoptosis | CDK 结构分类：抗生素 | 疾病研究 | 抗菌 | 抗生素 | 其他类 | 结构分类 In Vitro: Toyocamycin (0-0.3 μM; 4 h) inhibits ER stress-induced XBP1 mRNA splicing, and selectively inhibits the ER stress-induced activation of the IRE1α-XBP1 pathway. Toyocamycin (0-0.3 μM; 24 h) inhibits constitutive activation of XBP1 in MM cell lines. Toyocamycin (250 nM; 48 h) inhibits CDK9 enzymatic activity in colon cancer cell lines. Toyocamycin (0.05 nM-50 μM; 48 h and 72 h) doesn’t trigger immediate cytotoxicity against YB5 and HCT116 cells with cell viability above 50%, but results eradication of cancer cells 2 weeks later at 10 nM for 24 h treatment. Toyocamycin (0-100 nM; 24 or 48 h) induces apoptosis via mitochondrial pathway in PC-3 cells. Toyocamycin (60 nM; 0-48 h) promotes p38/ERK MAPK activation and regulates ROS-mediated apoptosis by inhibition of p38 on ERK MAPK. In Vivo: Toyocamycin (0.5 mg/kg, 1.0 mg/kg; i.p.; twice a week; 2 weeks) shows anti-tumor activity in a xenograft model with human multiple myeloma (MM) cells, while the anti-tumor effect enhanced by Bortezomib (HY-10227). 相关产品：Natural Product Library Plus | Bioactive Compound Library Plus | Anti-Infection Compound Library | Apoptosis Compound Library | Cell Cycle/DNA Damage Compound Library | Kinase Inhibitor Library | Natural Product Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Antifungal Compound Library | Endoplasmic Reticulum Stress Compound Library | Antibiotics Library | Anti-Breast Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Microbial Metabolite Library | Anti-Cancer Natural Product Library | Cancer Stem Cells Compound Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Highly Selective Inhibitors Library | Highly Selective Activators Library | Cell Death Library | Serine/Threonine Kinase Inhibitor Library | Anti-Hematopathy Compound Library | Anti-Ovarian Cancer Compound Library | Multi-Target Compound Library | Bioactive Compound Library Max | MG-132 | Rapamycin | Ferrostatin-1 | Cycloheximide | Chloroquine | Doxorubicin hydrochloride | Bafilomycin A1 | Tamoxifen | Y-27632 | LY294002 | Paclitaxel | Dexamethasone | Z-VAD-FMK | Acetylcysteine | Angiotensin II human | 2-Deoxy-D-glucose | Puromycin dihydrochloride | Staurosporine | Actinomycin D | SB-431542 | 5-Fluorouracil | Bortezomib | Deferoxamine mesylate | Oxaliplatin | Trametinib | Sorafenib | Temozolomide | Gemcitabine | Palbociclib | Decitabine 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。